Key result
Plasma proteomic profiling in arrhythmogenic cardiomyopathy identifies dysregulated desmosomal proteins as potential diagnostic biomarkers.
Observational
Plasma proteomics can identify unique desmosomal protein dysregulation in ACM, highlighting potential biomarkers to improve diagnostic accuracy.
May support desmosomal biomarker discovery in ACM; leaves open diagnostic utility pending prospective validation.
The plasma proteomic profiling of ACM suggests that ACM is a distinct disease entity characterized by a unique dysregulation of desmosomal proteins. The identification of plasma biomarkers associated with ACM underscores their potential to improve diagnostic accuracy and facilitate early intervention strategies. Further exploration of mutations in desmosomal proteins and their phosphorylation states may provide deeper insights into the pathophysiology of ACM.
No takes yet. Share an insight, caveat, or question.
Zarrouk‐Mahjoub et al. (2025) conducted an observational in Arrhythmogenic Cardiomyopathy (ACM). Plasma proteomic profiling was evaluated on Identification of plasma biomarkers. Plasma proteomic profiling of arrhythmogenic cardiomyopathy identified unique dysregulation of desmosomal proteins, highlighting potential biomarkers to improve diagnostic accuracy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: